| answer text |
<p>NHS England has advised that its Neuroscience Clinical Reference Group (CRG) carefully
reviewed the clinical evidence for the treatment of advanced Parkinson’s disease with
Duodopa (co-careldopa) and made a recommendation to the Clinical Priorities Advisory
Group (CPAG).</p><p> </p><p> </p><p> </p><p>CPAG accepted the CRG’s recommendation
that Duodopa should not be routinely commissioned for treatment of this condition
and, in turn, made this recommendation to the Directly Commissioned Services Committee
of the NHS England Board. The Board committee endorsed the recommendation in June
2014.</p><p> </p><p> </p><p> </p><p>Both patients and carers were involved in the
decision-making process. There are four patient /carer representatives on the CRG,
and patient and public stakeholders registered with the CRG were given an opportunity
to feed in their views before the Group made its recommendations to CPAG. CPAG’s membership
includes a lay chair and four patient representatives.</p><p> </p><p> </p><p> </p><p>Further
work has been undertaken on Duodopa since NHS England’s Board endorsed CPAG’s decision
in June 2014 and NHS England will reconsider whether or not to commission this treatment,
alongside a number of other specialised treatments, later this year.</p><p> </p>
|
|
